Illumina, Inc. ILMN
We take great care to ensure that the data presented and summarized in this overview for ILLUMINA, INC. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding ILMN
View all-
Black Rock Inc. New York, NY18.1MShares$2.59 Billion0.04% of portfolio
-
Vanguard Group Inc Valley Forge, PA15.9MShares$2.28 Billion0.04% of portfolio
-
State Street Corp Boston, MA5.61MShares$803 Million0.03% of portfolio
-
Loomis Sayles & CO L P4.34MShares$622 Million0.74% of portfolio
-
Baillie Gifford & CO3.62MShares$518 Million0.36% of portfolio
-
Capital World Investors Los Angeles, CA3.54MShares$507 Million0.07% of portfolio
-
Wcm Investment Management, LLC Laguna Beach, CA3.26MShares$467 Million1.1% of portfolio
-
Geode Capital Management, LLC Boston, MA2.73MShares$390 Million0.03% of portfolio
-
Guardcap Asset Management LTD London, X02.72MShares$390 Million4.84% of portfolio
-
Primecap Management CO Pasadena, CA2.52MShares$360 Million0.25% of portfolio
Latest Institutional Activity in ILMN
Top Purchases
Top Sells
About ILMN
Illumina, Inc. provides sequencing and array-based solutions for genetic and genomic analysis. Its products and services serve customers in a range of markets enabling the adoption of genomic solutions in research and clinical settings for applications in the life sciences, oncology, reproductive health, agriculture, and other emerging segments. The company provides instruments and consumables used in genetic analysis; and genotyping and sequencing services, instrument service contracts, and development and licensing agreements, as well as cancer detection testing services. Its customers include genomic research centers, academic institutions, government laboratories, and hospitals, as well as pharmaceutical, biotechnology, commercial molecular diagnostic laboratories, and consumer genomics companies. The company markets and distributes its products directly to customers in North America, Europe, Latin America, and the Asia-Pacific region, as well as sells through life-science distributors in various markets within Europe, the Asia-Pacific region, Latin America, the Middle East, and Africa. The company was incorporated in 1998 and is based in San Diego, California.
Insider Transactions at ILMN
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Dec 06
2024
|
Christensen Jakob Wedel SVP, Strategy/Corp Development |
SELL
Payment of exercise price or tax liability
|
Direct |
396
-5.53%
|
$55,440
$140.02 P/Share
|
|
Nov 05
2024
|
Steven Barnard SVP, Chief Technology Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
476
-1.73%
|
$73,304
$154.96 P/Share
|
|
Nov 05
2024
|
Carissa Rollins SVP, Chief Information Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
412
-3.43%
|
$63,448
$154.96 P/Share
|
|
Nov 05
2024
|
Scott M Davies Interim General Counsel |
SELL
Payment of exercise price or tax liability
|
Direct |
474
-3.42%
|
$72,996
$154.96 P/Share
|
|
Nov 05
2024
|
Scott D Ericksen VP, Chief Accounting Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
257
-2.37%
|
$39,578
$154.96 P/Share
|
|
Nov 05
2024
|
Kevin Carl Pegels Chief of Global Operations |
SELL
Payment of exercise price or tax liability
|
Direct |
699
-4.1%
|
$107,646
$154.96 P/Share
|
|
Nov 05
2024
|
Patricia Leckman SVP, Chief People Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
357
-2.23%
|
$54,978
$154.96 P/Share
|
|
Oct 05
2024
|
Jacob Thaysen Chief Executive Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
914
-2.02%
|
$127,960
$140.66 P/Share
|
|
Sep 30
2024
|
Scott B. Ullem Director |
BUY
Grant, award, or other acquisition
|
Direct |
183
+3.72%
|
$22,326
$122.78 P/Share
|
|
Sep 13
2024
|
Charles Dadswell SVP, General Counsel |
SELL
Sale (or disposition) back to the issuer
|
Indirect |
989
-4.58%
|
$124,614
$126.95 P/Share
|
|
Sep 05
2024
|
Steven Barnard SVP, Chief Technology Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
286
-1.03%
|
$36,894
$129.76 P/Share
|
|
Aug 15
2024
|
Charles Dadswell SVP, General Counsel |
SELL
Sale (or disposition) back to the issuer
|
Indirect |
989
-4.38%
|
$121,647
$123.56 P/Share
|
|
Jul 05
2024
|
Everett Cunningham SVP, Chief Commercial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
36,860
+50.0%
|
-
|
|
Jun 28
2024
|
Scott B. Ullem Director |
BUY
Grant, award, or other acquisition
|
Direct |
205
+4.31%
|
$22,345
$109.65 P/Share
|
|
May 16
2024
|
Anna Richo Director |
BUY
Grant, award, or other acquisition
|
Direct |
2,622
+50.0%
|
-
|
|
May 16
2024
|
Caroline Dorsa Director |
BUY
Grant, award, or other acquisition
|
Direct |
2,622
+17.42%
|
-
|
|
May 16
2024
|
Scott Gottlieb Director |
BUY
Grant, award, or other acquisition
|
Direct |
2,622
+24.25%
|
-
|
|
May 16
2024
|
Robert S Epstein Director |
BUY
Grant, award, or other acquisition
|
Direct |
2,622
+12.53%
|
-
|
|
May 16
2024
|
Frances Arnold Director |
BUY
Grant, award, or other acquisition
|
Direct |
2,622
+13.23%
|
-
|
|
May 16
2024
|
Stephen P Macmillan Director |
BUY
Grant, award, or other acquisition
|
Direct |
2,622
+38.84%
|
-
|
Last 12 Months Summary
| Grant, award, or other acquisition | 151K shares |
|---|---|
| Open market or private purchase | 7.33K shares |
| Payment of exercise price or tax liability | 5.62K shares |
|---|---|
| Sale (or disposition) back to the issuer | 1.98K shares |